Lumexa Imaging Holdings, Inc. (LMRI) · Aug 12, 2026 · Earnings

A small revenue beat hides Lumexa’s bigger margin problem

Beat — Revenue $264.2M vs ~$263.1M consensus; adjusted EPS $0.20 vs ~$0.12

Lumexa beat Q2 revenue and EPS estimates, but flat adjusted EBITDA and lower margins leave the outlook largely unchanged.

The quarter cleared modest expectations. Revenue was $264.2 million versus a published consensus of roughly $263.1 million, while adjusted EPS reached $0.20 against a published estimate near $0.12. That makes this a beat, though not a major top-line surprise. (Financial Highlights)

MetricQ2 2026Q2 2025 / expectation
Revenue$264.2M$251.4M; ~$263.1M consensus
Adjusted EPS$0.20$0.08; ~$0.12 consensus
GAAP EPS$0.03$(0.10); ~$0.02 consensus
Adjusted EBITDA$56.4M$56.3M
Adjusted EBITDA margin21.4%22.4%
Consolidated advanced procedure growth6.8%—

The operating engine is growing, but not converting that growth into incremental EBITDA. Consolidated revenue rose 5.1%, and advanced outpatient volumes grew 6.8%, with same-center advanced volume up 5.2%. Yet adjusted EBITDA was essentially flat at $56.4 million, and the margin fell 100 basis points to 21.4%. (Financial Highlights) (Q2 2026 Outpatient Volumes Highlights) (Adjusted EBITDA reconciliation)

The earnings beat was helped by lower financing costs rather than a cleaner operating result. Operating income declined to $23.0 million from $27.7 million as cost of operations and general and administrative expenses grew faster than revenue. Interest expense fell sharply to $16.2 million from $30.1 million, helping net income turn positive at $2.7 million from a $7.2 million loss. (Condensed Consolidated Statements of Operations)

Management left the annual framework intact, which limits the incremental information. Revenue guidance remained $1.045 billion to $1.097 billion, adjusted EPS stayed at $0.71 to $0.77, and the adjusted EBITDA midpoint remained $238 million. The EBITDA range was narrowed from $234 million–$242 million to $235 million–$241 million, but that is refinement rather than a forecast increase. (2026 Full Year Outlook) The company also acknowledged that approximately $7 million of public-company costs reduce expected 2026 adjusted EBITDA growth from 7% to 4% versus 2025. (2026 Full Year Outlook)

Net read: a real but narrow beat, with margin pressure keeping the signal contained. The filing improves the near-term scorecard through better-than-expected EPS and slightly above-consensus revenue, but flat adjusted EBITDA and unchanged guidance do not yet demonstrate stronger full-year earnings power.

Original filing on SEC EDGAR

A small revenue beat hides Lumexa’s bigger margin problem | LMRI Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.